Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University Innovation’s management consultancy division to restructure as separate entity to scale up interactions and business on the world stage.

Isis Enterprise, the global innovation management consultancy division of Oxford University Innovation, will be joining Oxford University’s ever-growing list of innovative companies as it rebrands to Oxentia and establishes itself a separate entity later this year.

Established in 2004 to offer technology transfer support and training to universities, research organisations and governments, Isis Enterprise has expanded its range of services and now works with organisations around the world. As a result of this growth and to better serve its extensive client base, Isis Enterprise will transition from a division of Oxford University Innovation to a limited company during the third quarter of 2017.

Read more (Oxford University Innovation website)

Similar stories

Oxford joins consortium to advance quantum drug discovery with £6.8M grant from Innovate UK

Oxford University today joins a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.